Recent and Upcoming Changes
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
23 April 2020 Update
20 April – 23 April 2020 Contents I. Summary .............................................................................................................................1 II. European Union .................................................................................................................5 III. France ...............................................................................................................................6 IV. Italy ...................................................................................................................................7 V. Germany ............................................................................................................................8 VI. Spain ...............................................................................................................................10 VII. United Kingdom .............................................................................................................10 I. SUMMARY Number of cases: 1,009,762 (including the UK) Number of deaths: 108,223 • The EU Executive Steering Group on Shortages of Medicines Caused by Major Events held a meeting on 15 April to discuss the progress of the measures regarding availability of medicines for European patients during the COVID-19 pandemic. They also updated the Q&A document on regulatory expectations for medicinal products for human use during the COVID-19 pandemic on 20 April. On 21 April, they set-up the fast-track system to support essential medicines for COVID-19 treatment, -
Report of the Global Travel Taskforce: the Safe Return of International Travel
Report of the Global Travel Taskforce The Safe Return of International Travel Presented to the Prime Minister by the Secretary of State for Transport April 2021 Department for Transport Great Minster House 33 Horseferry Road London SW1P 4DR © Crown copyright 2021 This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3. The National Archives at www.nationalarchives.gov.uk/contact-us. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. This publication is also available on our website at www.gov.uk/government/organisations/department-for-transport. Any enquiries regarding this publication should be sent to us at www.gov.uk/government/organisations/department-for-transport Contents Foreword: Statement from the Secretary of State for Transport 2 1 Executive summary 4 Recommendations 5 2 The safe return of international travel 7 3 A risk-based approach to reopening international travel 9 Towards a risk-based framework 9 A risk-based approach 9 Health measures for arrivals 10 Checkpoints and transition to future travel 11 Restart of the cruise sector 12 4 Readiness for international travel restart 13 Border readiness 13 Safety 13 5 Consumer clarity and confidence 15 Communications and confidence 15 Consumer protections 16 6 Transition to future travel 17 Working together towards common global standards 17 Travel certification 18 1 Report of the Global Travel Taskforce – The Safe Return of International Travel Foreword In February, the Prime Minister asked me to develop the framework for a safe and sustainable return to non-essential international travel when the time is right. -
Home Office Preparedness for COVID-19 (Coronavirus): Management of the Borders: Government Response to the Committee’S Fifth Report
House of Commons Home Affairs Committee Home Office preparedness for COVID-19 (coronavirus): management of the borders: Government Response to the Committee’s Fifth Report Sixth Special Report of Session 2019–21 Ordered by the House of Commons to be printed 11 November 2020 HC 974 Published on 13 November 2020 by authority of the House of Commons Home Affairs Committee The Home Affairs Committee is appointed by the House of Commons to examine the expenditure, administration, and policy of the Home Office and its associated public bodies. Current membership Yvette Cooper MP (Labour, Normanton, Pontefract and Castleford) Chair Diane Abbott MP (Labour, Hackney North and Stoke Newington) Dehenna Davison MP (Conservative, Bishop Auckland) Ruth Edwards MP (Conservative, Rushcliffe) Laura Farris MP (Conservative, Newbury) Simon Fell MP (Conservative, Barrow and Furness) Andrew Gwynne MP (Labour, Denton and Reddish) Adam Holloway MP (Conservative, Gravesham) Dame Diana Johnson MP (Labour, Kingston upon Hull North) Tim Loughton MP (Conservative, East Worthing and Shoreham) Stuart C McDonald MP (Scottish National Party, Cumbernauld, Kilsyth and Kirkintilloch East) Powers The Committee is one of the departmental select committees, the powers of which are set out in House of Commons Standing Orders, principally in SO No 152. These are available on the internet via www.parliament.uk. Publications © Parliamentary Copyright House of Commons 2020. This publication may be reproduced under the terms of the Open Parliament Licence, which is published at www.parliament.uk/site-information/copyright-parliament/. Committee reports are published on the Committee’s website at www.parliament.uk/homeaffairscom and in print by Order of the House. -
Written Evidence from Spotlight on Corruption1 (PGG18) the Public
Written evidence from Spotlight on Corruption1 (PGG18) The Public Administration and Constitutional Affairs Committee Propriety of governance in light of Greensill inquiry Introduction The revelations arising from the Greensill affair and its fallout, coming alongside other recent and ongoing scandals, have exposed significant weaknesses in the UK system for managing conflicts of interest, lobbying, and business appointments. This is a vital opportunity to bring the UK’s standards landscape up to date, and to ensure that integrity and ethics in government are regulated in a way that befits a modern democracy. Taking action to strengthen the UK’s integrity and ethics framework would benefit the UK by helping to: build trust in politicians and government; strengthen the stability, predictability and attractiveness of the UK as a place to do business; give the UK greater credibility on the international stage in promoting democracy and good governance; and implement outstanding recommendations made by international bodies such as the UN and Council of Europe about how the UK can improve its integrity and ethics framework to prevent and tackle corruption. Key Recommendations 1. Integrity and Ethics legislation. The government should consult on the introduction of an Integrity and Ethics Bill, by the spring of 2022, which gives legislative effect to: the Law Commission’s recommendations on the introduction of a corruption in public office offence; recommendations made by international bodies to put ACOBA and the Independent Advisor on Ministerial Interests on a statutory footing; recommendations that are likely to be made by the Committee on Standards in Public Life’s Standards Matters 2.0 review in the Autumn of 2021; and recommendations likely to be made from both the Boardman review and parliamentary committees such as PACAC, including legislative reform to the Lobbying Act. -
UK COVID-19 Vaccines Delivery Plan
UK COVID-19 vaccines delivery plan Published 11 January 2021 Contents 1. Ministerial foreword ....................................................................................................... 3 2. Executive summary and scope ..................................................................................... 4 Supply .............................................................................................................................. 5 Prioritisation ...................................................................................................................... 6 Places ............................................................................................................................... 7 People .............................................................................................................................. 8 Tracking our progress ....................................................................................................... 9 3. Supply ......................................................................................................................... 10 Developing new vaccines ............................................................................................... 10 Ensuring vaccines meet strict safety standards for deployment ..................................... 17 Building UK manufacturing capability ............................................................................. 21 4. Prioritisation ............................................................................................................... -
Covid-19 INNOVA Testing in Schools: Don’T Just Test, Evaluate
Covid-19 INNOVA testing in schools: don’t just test, evaluate Using testing to manage classroom outbreaks, without isolating close contacts, risks increasing disease spread, say these authors Everybody wants schools to reopen when it is safe to do so, but for pupils, teachers, and their communities to remain safe they must stay close to covid free. Last term, schools limited pupil mixing and activities, and isolated pupil groups at home once a covid-19 case was identified, although many struggled with the lack of clear guidance. This term the government is planning to rely on INNOVA rapid lateral flow tests to mass screen staff and pupils, and serial test close school-contacts of covid cases. [1] The proposed strategies were announced to schools on the last day of term before the Christmas break, providing no time for schools to scrutinise and discuss their scientific basis, or to organise how the lateral flow test policy will be delivered. Lockdown now provides an opportunity to do this, albeit some schools have already started using tests in keyworkers’ children who continue to attend. There are two different components to the government’s testing plan. The first, mass testing of staff and pupils on return and twice weekly thereafter, aims to detect individuals who have asymptomatic or pre-symptomatic infection. Using the test to identify infected individuals who successfully isolate and prevent onward transmission is a clearly good outcome. However, there are three questions to ask: first, whether other testing strategies could produce better outcomes; second, could the same or fewer resources be more effectively used in other ways to contain infection; and third, whether there are likely to be unintended consequences of testing which could counter any benefit. -
Open PDF 502KB
COR0251 Supplementary written evidence submitted by Kelley Lee, Julianne Piper and Benoit Gomis, Pandemics and Borders Project, Faculty of Health Sciences, Simon Fraser University, Canada (COR0251) WHAT ARE YOUR MAIN RECOMMENDATIONS FOR EFFECTIVE BORDER MANAGEMENT OVER THE NEXT 12 MONTHS? 1. The UK, and other countries with rising vaccination levels, are entering a challenging period in relation to border management. Increased vaccination means lower transmission and thus pressures to relax public health measures including increased travel domestically and abroad. At the same time, the volume of circulating virus globally, new variants continue to evolve, with those more transmissible and virulent, and/or vaccine-evasive VOC moving the goalposts on herd immunity. 2. Most disruptive would be if a partial-escape variant emerges, i.e., one able to infect a significant number of fully vaccinated people and cause severe disease. A recent study modelled different scenarios in Canada for vaccine coverage and efficacy. The most damaging, by far, was a partial-escape variant. COVID-19 cases, hospitalizations and deaths were predicted to be twice as high as the next most serious scenario.1 Even with 75% full vaccination of the total population (Canada’s present target for the end of the summer), a partial-escape variant could result in a fourth wave. Even at 90% full vaccination, the study showed a partial-escape variant would be disruptive. 3. Effective management of travel-related risks will thus be critical over next 12-18 months, particularly given slow progress on achieving global equity in access to vaccines. There are risks to the gains achieved from mass vaccination. -
COVID-19 Interim Vaccination Plan V.5 Pennsylvania
COVID-19 Interim Vaccination Plan V.5 Pennsylvania PA COVID-19 Vaccine Task Force/PA Department of Health JANUARY 19, 2021 |VERSION 5.0 PENNSYLVANIA COVID-19 INTERIM VACCINATION PLAN Table of Contents Introduction……………………………………………………………………………………………………………………………………….2 Section 1: COVID-19 Vaccination Preparedness Planning ......................................................................... 3 Section 2: COVID-19 Organizational Structure and Partner Involvement ................................................. 4 Section 3: Phased Approach to COVID-19 Vaccination ........................................................................... 11 Section 4: Critical Populations ................................................................................................................. 17 Section 5: COVID-19 Provider Recruitment and Enrollment ................................................................... 21 Section 6: COVID-19 Vaccine Administration Capacity ........................................................................... 25 1. Health and Medical Infrastructure .......................................................................................... 25 2. Occupational Health Clinics and Closed Points of Dispensing (PODs) ..................................... 26 3. Expanded Outreach to Ensure Vaccine Access ........................................................................ 27 4. Staffing .................................................................................................................................... -
Daily Report Thursday, 14 January 2021 CONTENTS
Daily Report Thursday, 14 January 2021 This report shows written answers and statements provided on 14 January 2021 and the information is correct at the time of publication (06:29 P.M., 14 January 2021). For the latest information on written questions and answers, ministerial corrections, and written statements, please visit: http://www.parliament.uk/writtenanswers/ CONTENTS ANSWERS 7 Police and Crime BUSINESS, ENERGY AND Commissioners: Elections 15 INDUSTRIAL STRATEGY 7 Schools: Procurement 16 Additional Restrictions Grant 7 Veterans: Suicide 16 Business: Coronavirus 7 DEFENCE 17 Business: Grants 8 Armed Forces: Health Conditions of Employment: Services 17 Re-employment 9 Defence: Expenditure 17 Industrial Health and Safety: HMS Montrose: Repairs and Coronavirus 9 Maintenance 18 Motor Neurone Disease: HMS Queen Elizabeth: Research 10 Repairs and Maintenance 18 Podiatry: Coronavirus 11 DIGITAL, CULTURE, MEDIA AND Public Houses: Coronavirus 11 SPORT 19 Wind Power 12 British Telecom: Disclosure of Information 19 CABINET OFFICE 13 Broadband: Elmet and Civil Servants: Business Rothwell 20 Interests 13 Broadband: Greater London 20 Coronavirus: Disease Control 13 Chatterley Whitfield Colliery 21 Coronavirus: Lung Diseases 13 Data Protection 22 Debts 14 Educational Broadcasting: Fisheries: UK Relations with Coronavirus 23 EU 14 Events Industry and Iron and Steel: Procurement 14 Performing Arts: Greater National Security Council: London 23 Coronavirus 15 Football: Dementia 24 Football: Gambling 24 Organic Food: UK Trade with Freedom of Expression -
Role and Responsibilities of the Chair of the Vaccine Taskforce
Chair of the Vaccine Taskforce Information pack for applicants Closing date: Midday on Friday 14 May 2021 Reference no: VAC-1775 Follow us on Twitter @appointmentsdh Table of Contents Section 1: Role, responsibilities and person specification.................................................... 2 Section 2: How to apply ....................................................................................................... 4 2.1 Making an application ............................................................................................. 4 2.2 The selection process ............................................................................................. 7 2.3 Eligibility criteria ...................................................................................................... 9 2.4 How we will manage your personal information .................................................... 10 Chair of the Vaccine Taskforce - Information pack for applicants Section 1: Role and responsibilities of the Chair of the Vaccine Taskforce The Chair must enable the Vaccine Taskforce to achieve their three core objectives during the pandemic period: a. To secure access to promising vaccine/s for the UK population. b. To make provision for international distribution of vaccines. c. To strengthen the UK’s onshore capacity and capability in vaccine development, manufacturing, and supply chain to provide resilience for this and future pandemics. In recognising that the Taskforce has now been in existence for over a year, delivering these objectives -
Countries Entry Instructions 1- MIDDLE EAST: No
Countries entry instructions 1- MIDDLE EAST: No. Country Instructions & Restrictions 1 EGYPT Health Regulations to enter Egypt: Passengers should wear face masks during the flight. A Health Declaration form should be available on all the international flights and to be filled by the Passengers before boarding the flight (at the departure airport) and to be delivered to The Quarantine Authorities upon arrival. Airline must provide the Health Declaration form at the departure airports and insure that the passengers have filled and signed it before boarding the flight (on the international flights) Passengers travelling to Egypt should be screened at the airport of departure. Passengers who are suffering from a temperature (Equal / above) 38C or those who are suffering from one of the respiratory symptoms (cough / sneezing / shortness of breath …etc.) are not allowed to board the aircraft. Aircraft disinfection form should be delivered to The Quarantine Authorities upon arrival for the international flights. The disinfection of the Aircraft and the disinfection of aircraft air conditions filters should be done according to WHO guidelines and the aircraft manufacturer, Aircraft will not be allowed to take off again till obtaining a sanitary quarantine approval from the Egyptian Quarantine Authorities. In case of any of the respiratory symptoms appear on a passenger during the flight, all necessary precautions must be taken if possible by (separate the suspected passenger in an area far from the rest of the passengers / assign one of the cabin crew members to serve the sick passenger / provide a bathroom for the sick passenger only). Global Health insurance is no more mandatory. -
20200424-Covid 19-Part 5 Week 10-23
List of Annexes Annex 1 China ......................................................................................................................................... 3 Annex 2 Taiwan .................................................................................................................................... 40 Annex 3 Japan ....................................................................................................................................... 62 Annex 4 South Korea ............................................................................................................................ 65 Annex 5 Italy ......................................................................................................................................... 77 Annex 6 Portugal ................................................................................................................................... 84 Annex 6 Spain ....................................................................................................................................... 91 Annex 8 Belgiun .................................................................................................................................. 103 Annex 9 Germany ............................................................................................................................... 108 Annex 10 The Netherlands .................................................................................................................. 114 Annex 11 France ................................................................................................................................